Equities

ScinoPharm Taiwan Ltd

1789:TAI

ScinoPharm Taiwan Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)25.15
  • Today's Change0.25 / 1.00%
  • Shares traded371.87k
  • 1 Year change-7.02%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,9424,3464,132
Total Receivables, Net813654393
Total Inventory1,5121,1891,345
Prepaid expenses10613297
Other current assets, total8.30----
Total current assets6,3816,3205,967
Property, plant & equipment, net4,5784,7974,883
Goodwill, net------
Intangibles, net199.958.79
Long term investments101144215
Note receivable - long term------
Other long term assets2.392.552.52
Total assets11,72211,91111,691
LIABILITIES
Accounts payable10212671
Accrued expenses140140125
Notes payable/short-term debt32780
Current portion long-term debt/capital leases181818
Other current liabilities, total438442343
Total current liabilities729803556
Total long term debt570581540
Total debt620677558
Deferred income tax1.6600.35
Minority interest------
Other liabilities, total567783
Total liabilities1,3571,4611,180
SHAREHOLDERS EQUITY
Common stock7,9077,9077,907
Additional paid-in capital1,2951,2951,295
Retained earnings (accumulated deficit)1,3481,3461,370
Treasury stock - common------
Unrealized gain (loss)(98)(55)18
Other equity, total(88)(43)(79)
Total equity10,36410,45010,511
Total liabilities & shareholders' equity11,72211,91111,691
Total common shares outstanding791791791
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.